RxSight, Inc. Reports 28 Percent Revenue Growth in First Quarter 2025, Reiterates Full-Year Guidance

Published on May 9, 2025
ALISO VIEJO, Calif.—RxSight, Inc., an ophthalmic medical device company providing customized vision to patients following cataract surgery, has reported financial results for the first quarter for the period ending March 31, 2025. In the first quarter of 2025, total revenue was $37.9 million, an increase of 28 percent compared with $29.5 million in the first quarter of 2024. According to the company, revenue growth was driven by a 37 percent increase in Light Adjustable Lens (LAL) revenue and an 8 percent increase in Light Delivery Device (LDD) revenue, compared with the first quarter of 2024.
Continue reading on website
Other news

CIME 2025: Luke Lindsell, OD, MD, on bridging innovation and practical care in retinal disease

May 8, 2025
Lindsell discusses promising retinal therapeutics, such as at-home therapies, gene therapy, and devices like the Valeda light delivery system (LumiThera), which uses photobiomodulation and shows early promise in preventing geographic atrophy altogether.

Prevent Blindness voices support for reintroduction of EDVI Act

May 9, 2025
The Early Detection of Vision Impairments for Children Act (EDVI), or HR 2527, would allow the federal government to award grants and cooperative agreements to eligible states and communities for children's vision care initiatives.